Aradigm

 

HomeAboutProductsTechnologiesInvestorsCareers

 

 

Intellectual Property

AERx Inhalation Technology Platform

Liposomal Formulations

Aradigm actively seeks to protect its technologies and products, including Lipoquin and Pulmaquin in clinical development, as reflected in the Company's intellectual property estate. The bulk of the patents and patent applications contain claims directed toward the Company's proprietary compositions and methods of treatment using those compositions, pharmaceutical formulations, delivery technologies, including methods for aerosol generation, devices used to generate aerosols, breath control, compliance monitoring, design of dosage forms and their manufacturing and testing methods. Aradigm also seeks to protect its products by supplementing its intellectual property with regulatory protection such as orphan drug designation and through trade secrets, such as confidential processes, methods and technologies.

Aradigm has the following recently issued US patents and published patent applications which relate to the Lipoquin and Pulmaquin products in development:

US#: 9,259,424. Cipolla D and Blanchard J. Concentrated, Inhalable Antibiotic Formulation. February 16, 2016.

US#: 9,078,897. Cipolla D and Blanchard J. Concentrated, Inhalable Antibiotic Formulation. July 14, 2015.

US#: 9,028,864. Cipolla D and Blanchard J. Concentrated, Inhalable Antibiotic Formulation. May 12, 2015.

US#: 8,414,915. Cipolla D and Blanchard J. Dual Action, Inhaled Formulations Providing Both an Immediate and Sustained Release Profile. April 9, 2013.

US#: 8,268,347. Cipolla D and Blanchard J. Dual Action, Inhaled Formulations Providing Both an Immediate and Sustained Release Profile. September 18, 2012.

US#: 8,119,156. Cipolla D and Blanchard J. Dual Action, Inhaled Formulations Providing Both an Immediate and Sustained Release Profile. February 21, 2012.

US#: 8,071,127. Cipolla D and Blanchard J. Dual Action, Inhaled Formulations Providing Both an Immediate and Sustained Release Profile. December 6, 2011.

US 2015-0283133. Gonda I, Blanchard J, Cipolla D and Bermudez L. Liposomal Ciprofloxacin Formulations with Activity against Non-Tuberculous Mycobacteria. 10/8/2015

US 2015-0283076. Cipolla D and Gonda I. Novel Liposomal Formulations that form Drug Nanocrystals after Freeze-Thaw. 10/8/2015

US 2015/0110855. Cipolla D and Gonda I. Inhaled Surfactant-Modified Liposomal Formulations Providing Both and Immediate and Sustained Release Profile. 4/23/2015

US 2015/0071992. Cipolla D and Blanchard J. Concentrated, Inhalable Ciprofloxacin Formulation. 3/12/2015.

US 2012/0282328. Cipolla D and Blanchard J. Dual Action, Inhaled Formulations Providing Both an Immediate and Sustained Release Profile. 11/8/2012.

The Company has been involved in in- and out-licensing intellectual property for business purposes. If interested in licensing IP, please contact; IP@aradigm.com

 

 

 

 

 

 

 

 

 

 

CONTACT NEWS & EVENTS LEGAL SITE MAP

2016 Aradigm Corporation. All Rights Reserved.